Company Profile

ESA Biosciences Inc (AKA: Environmental Sciences Associates Inc~ESA Biosciences Inc)
Profile last edited on: 2/7/19      CAGE: 0PJA1      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1970
First Award
1984
Latest Award
2001
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

22 Alpha Road
Chelmsford, MA 01824
   (978) 250-7000
   info@esainc.com
   www.esainc.com
Location: Multiple
Congr. District: 03
County: Middlesex

Public Profile

In September 2009, ESA Inc was acquired by Dionex Corp, which has itself been acquired by Thermo-Fisher. ESA Inc, is now a subsidiary of Thermo Fisher Diagnostics. Originally called Environmental Sciences Associates, Inc., now known as ESA, the firm developed a technique to measure lead - an instrument based on an electrochemical technique called anodic stripping voltammetry, or ASV, the first practical method to screen children for blood lead poisoning. The firm shifted focus to researching the neurochemical damage caused by lead poisoning. The firm developed a flow-through electrochemical cell, made out of porous graphite as an alternative to using HPLC with electrochemical detection - the only type of detectors then available used thin-layer or flow across electrodes. This cell design proved to be more stable, selective and generally more sensitive than the thin-layer cells. To utilize the new EC cell, ESA developed the Coulochem® Detector and later complemented this with a complete line of HPLC equipment optimized for EC detection. ESA continued research into areas such as Huntington's, Parkinson's and Alzheimer's Disease. Addressing the disagreement in the neurochemistry community on the level of serotonin (a neurotransmitter) in various areas of the brain, the principal of the firm postulated that what researchers were calling serotonin was actually more than one compound. To investigate this assumption, he assembled four Coulochem detectors and eight chart recorders, and began running samples through eight flow-through electrodes set at increasingly higher potentials. With this array of electrodes he discovered there was a compound co-eluting with serotonin which he was now able to resolve. This new instrument eventually became the current Model 5600 CoulArray® Detector which has moved from being primarily a neurochemical analyzer into virtually almost every type of scientific laboratory, from the food and beverage to the clinical and pharmaceutical industrie

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2001 1 NIH $91,902
Project Title: Technology For DNA Damage Markers In Cervical Cancer
1998 2 NIH $848,740
Project Title: Technology for Clinical Management of Oxidative Stress
1996 2 NIH $584,549
Project Title: Comparative model for immobility osteopneia
1993 2 NIH $550,000
Project Title: Integrated column/multisensor microbore system
1989 2 NIH $550,000
Project Title: Methods for kynurenine system in Huntington's disease

Key People / Management

  Walter DiGiusto -- President

  Robert J Rosenthal -- Chief Executive Officer, President and Director

  Wayne R Matson

  Paul E Milbury

Company News

There are no news available.